SCHEMBL140875

SCHEMBL140875

N#Cc1ccc(F)cc1Nc1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.57
LMNA P02545 2/20 0.55
TYK2 P29597 3/20 0.54
MAPK14 Q16539 1/20 0.49
NTRK1 P04629 2/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
JAK3 P52333 1/20 0.46
NAMPT P43490 1/20 0.45
LRRK2 Q5S007 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD11B1 P28845 1/20 0.44
PHGDH O43175 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27833935 0.84 TYK2 (0.55) EPHX2LMNATYK2JAK3NAMPT
SCHEMBL13284196 0.83 EPHX2 (0.60) EPHX2LMNATYK2MAPK14NTRK1
SCHEMBL149035 0.80 TYK2 (0.53) EPHX2LMNATYK2MAPK14JAK2
SCHEMBL142450 0.80 TYK2 (0.50) EPHX2LMNATYK2LRRK2SMN1; SMN2
SCHEMBL27852018 0.78 TYK2 (0.55) EPHX2LMNATYK2MAPK14JAK2
SCHEMBL27833923 0.78 TYK2 (0.59) EPHX2LMNATYK2JAK2JAK1
SCHEMBL27997814 0.77 MKNK1 (0.55) EPHX2NAMPTSMN1; SMN2PHGDHHPGD
SCHEMBL141118 0.76 TYK2 (0.55) EPHX2LMNATYK2MAPK14JAK2
SCHEMBL142118 0.76 TTK (0.51) TYK2JAK2LRRK2SMN1; SMN2HPGD
SCHEMBL144961 0.76 TYK2 (0.49) EPHX2LMNATYK2MAPK14JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
CN-102325752-A Carbazole and carboline kinase inhibitors BRISTOL MYERS SQUIBB CO 2012-01-18 CN disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 EPHX2 4348/4885LMNA 4273/4885TYK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.